Le réseau Unicancer à l’ASCO 2025

Dose expansion data from iintune-1, a phase 1/2 study of the STING agonist dazostinag plus pembrolizumab as first-line (1L), in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). Dr Jérôme Fayette

Abstract : Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial. Pr Jean-Yves Blay

Abstract: Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer. Dr Philippe Cassier

Abstract : A multicenter, open-label, proof-of-concept phase II trial evaluating NP137 as add-on therapy in advanced/metastatic solid tumors treated with standard immunotherapies. Dr Jérôme Fayette

Abstract: Comparable efficacy and safety of taletrectinib for advanced ROS1+ non–small cell lung cancer across pivotal studies and between races and world regions. Dr Maurice Pérol

Early results of the French multicenter, randomized SHARE trial comparing whole breast irradiation versus accelerated partial breast irradiation in postmenopausal women with early-stage low risk breast cancer: Analysis of toxicity and cosmetic outcomes. Yazid Belkacemi, Isabelle Gabelle Flandin, Marie-Cecile Le Deley, Clemence Leguillette, Kamel Debbi, Adeline Petit, Philippe Guilbert, Julien Geffrelot, Christian Carrie, Eleonor Rivin Del Campo, Chantal Hanzen, Claire Brunaud, Isabelle Lecouillard, Nicolas Magné, Emilie Bogart, Guillaume Auzac, Thomas Lacornerie, Jerome Lemonnier, Celine Bourgier, Eric Lartigau

Dose expansion data from iintune-1, a phase 1/2 study of the STING agonist dazostinag plus pembrolizumab as first-line (1L), in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). Jérôme Fayette, Aron Popovtzer, Martin D. Forster, Douglas Adkins, Ye Guo, Gautier Lefebvre, Jacob S. Thomas, Fiona J. Collinson, Ludovic Doucet, Nathaniel Bouganim, Lei Liu, Jaafar Bennouna, Richard C. Gregory, Cong Li, Radha Ramesh, Bingyan Wu, Jeffrey Raizer, Yu-Chung Huang, Ammar Sukari. Session orale ORL (01/06/2025)

NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. Jean Bourhis, Anne Auperin, Christian Borel, Gautier Lefebvre, Severine Racadot, Lionnel Geoffrois, Xu Shan Sun, Esma Saada, Beatriz Cirauqui, Tomasz Rutkowski, Stephanie Henry, Anouchka Modesto, Alison Johnson, Benoit Calderon, Yoann Pointreau, Elisabeth Perez Ruiz, Joanna Kazmierska, Amanda Psyrri, Ricard Mesia, Yungan Tao, GORTEC (01/06/2025)

ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72). Alexander Olawaiye, Laurence Gladieff, Lucy Gilbert, Jae-Weon Kim, Mariana Scaranti, Vanda Salutari, Elizabeth Hopp, Linda R. Mileshkin, Alix Devaux, Michael McCollum, Ana Oaknin, Aliza L. Leiser, Nicoletta Colombo, Andrew R. Clamp, Boglarka Balazs, Giuseppa Scandurra, Emilie Kaczmarek, Hristina I. Pashova, Sachin G. Pai, Domenica Lorusso (02/06/2025)

TIKIN Away: Expanding the Role of Tyrosine Kinase Inhibitors for the Treatment of Sarcomas. Nicolas Penel. Discussion session orale Sarcome (01/06/2025)

Predictive gene signature for the efficacy of pazopanib in solitary fibrous tumor: A Spanish Group for Research in Sarcoma (GEIS) study. David S. Moura, Jesus Lopez-Marti, Silvia Stacchiotti, Ana Sebio, Andres Redondo, Nicolas Penel, Jean-Yves Blay, Xavier Garcia del Muro, Giovanni Grignani, Josefina Cruz Jurado, Javier Martínez-Trufero, Antoine Italiano, Emanuela Palmerini, Daniel Bernabeu, Jose L. Mondaza-Hernandez, Nadia Hindi, Javier Martin Broto

IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers – The B3 Thymomas and Thymic Carcinomas Cohort. Michaël Duruisseaux, Benjamin Besse, Nicolas Girard, Eric Dansin, Sophie Cousin, Julien Mazieres, Ludovic Doucet, Anne Madroszyk, Laurent Greillier, Charles Ricordel, Sarah Cavaillon, Celine Mascaux, Cécile Vicier, Diego Tosi, Sara Calattini, Vérane Schwiertz, Sylvie Bin, Fabien Subtil, Benoit You, Thomas Pierret

Post-treatment MRI to predict pathological complete response in triple-negative breast cancer following neoadjuvant chemoimmunotherapy. Toulsie Ramtohul, Derek Lollivier, Justine Spriet, Maxime Jin, Lounes Djerroudi, Thomas Gaillard, Claire Bonneau, Delphine Loirat, Diana Bello Roufai, Youlia M. Kirova, Pierre Loap, Caroline Malhaire, Anne Vincent-Salomon, Francois Clement Bidard, Anne Tardivon, Audrey Mailliez, Lauren Wallaert, Luc Ceugnart, Caroline Nhy, Luc Cabel

Efficacy of tucatinib, trastuzumab, and capecitabine (TTC) following trastuzumab-deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (MBC): Updated results and subgroup analyses from the UNICANCER multicenter retrospective cohort. Jean-Sebastien Frenel, Jean Zeghondy, Catherine Guerin, Audrey Mailliez, Elsa Volant, Francois Poumeaud, Anne Patsouris, Monica Arnedos, Caroline Bailleux, Fanny Le Du, Loik Galland, Alexandre de Nonneville, Severine Guiu Lahaye, Barbara Pistilli, Florence Dalenc, Thomas Bachelot, Jean-Yves Pierga, Louis Larrouquere, Delphine Loirat

Phase Ib study of the combination of regorafenib with conventional chemotherapy in patients with newly diagnosed multi-metastatic Ewing sarcoma: The Rego-Inter-Ewing-1 study. Pablo Berlanga, Dan Chaltiel, Cyril Lervat, Nadege Corradini, Valerie Laurence, Stephane Ducassou, Lianne Havemann, Marianne Phillips, Jean Luc Joannic, Line Claude, Sandra J. Strauss, Roberto Luksch, Hans Merks, Karsten Nysom, Camille Tron, Tiphaine Adam de Beaumais, Claudia Valverde, Salim Laghouati, Bernadette Brennan, Nathalie Gaspar

Trajectories of multidimensional worry in survivors of early breast cancer (BC). Antonio Di Meglio, Martina Pagliuca, Stefano Maccarone, Julie Havas, Leonor Fasse, Diane Boinon, Marianne Hermand-Deslandes, Anne-Laure Martin, Catherine Gaudin, Christelle Jouannaud, Marion Fournier, Laurence Vanlemmens, Anne Kieffer, Baptiste Sauterey, François Cherifi, Florence Lerebours, Gwenn Menvielle, Stefan Michiels, Maria Alice Franzoi, Ines Luis

A hierarchical clustering approach to dissect behavioral symptoms in early-stage breast cancer (BC). Martina Pagliuca, Pietro Lapidari, Leonor Fasse, Diane Boinon, Marianne Hermand-Deslandes, Anne-Laure Martin, Dominique Delmas, Christelle Jouannaud, Marion Fournier, Laurence Vanlemmens, Coureche Kaderbhai, Anne Kieffer, Baptiste Sauterey, François Cherifi, Florence Lerebours, Michelino De Laurentiis, Stefan Michiels, Maria Alice Franzoi, Ines Luis, Antonio Di Meglio

Mechanisms of resistance to anti-PD1 treatment in recurrent and/or metastatic squamous cell carcinoma of the head and neck: A multi-omics IMMUCAN/EORTC analysis. Athenais van der Elst (02/06/2025). Athenais van der Elst, Daniel Herrero Saboya, Lucas Michon, Marie Morfouace, Robin Liechti, Daniel Schulz, Maya Persoons, Sylvie Rusakiewicz, Marie-Sophie Robert, Henoch Hong, Rachel Galot, Paolo Bossi, Florian Estrade, Julio Oliveira, Caroline Even, Sophie Lucas, Pierre Saintigny, Céline Lefebvre, Loredana Martignetti, Jean-Pascal H. Machiels (02/06/2025)

L’immunothérapie en renfort de la radio-chimiothérapie dans les cancers ORL à haut risque de rechute. Dr Yun Gan Tao

Une nouvelle stratégie ciblée pour les cancers colorectaux mutés KRAS G12C. Dr Antoine Hollebecque

Une combinaison innovante testée en première ligne dans le sarcome d’Ewing métastatique. Dr Pablo Berlanga

Gastrointestinal Cancer—Colorectal and Anal :

Immune checkpoint inhibitor (ICI) reuse after failure of first-line ICI in patients with metastatic dMMR/MSI gastrointestinal cancers: The INFLATE study. Dr Lola-Jade Palmieri

Lung Cancer—Non-Small Cell Metastatic :

Evaluation of the combination of regorafenib + avelumab in patients with non-small cell lung cancer without oncogenic addiction: The phase II REGOMUNE study. Dr Sophie Cousin

Developmental Therapeutics—Immunotherapy :

Biological determinants of immune exclusion in non-small cell lung cancer: An analysis of the precision medicine BIP study. Dr Florent Peyraud

Abstract LBA4 : Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial / Publi NEJM concommitente – Pr François Clément Bidard (last autor) – (Pr Nicholas C. Turner speaker)  

Abstract 10004 : Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: A data update from the iMATRIX alectinib phase I/II open-label, multi-center study. Pr François Doz

Abstract LBA8000 : Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816 / Publi NEJM concommitente. Pr Nicolas Girard (last autor) (Patrick M. Forde speaker) 

Abstract 8016 : Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial. Pr Nicolas Girard

Abstract 6016 : Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts). Pr Christophe Le Tourneau

Abstract 4009 : Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone after FOLFIRINOX (FFX) induction in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): Primary endpoint results of a randomized TEDOPAM GERCOR D17-01 PRODIGE 63 trial. Cindy Neuzillet

Abstract 8537 | Poster Bd 17
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung trial explores metastasis-associated alterations and potential prognostic markers.
Dr Abderaouf Hamza

Abstract TPS7083 | Poster Bd 266a
SOUNDTRACK-E: A phase 1/2, open-label, multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies.
Pr Steven Le Gouill

Abstract 7044 | Poster Bd 227
Ibrutinib, venetoclax plus CD20 monoclonal Ab: Initial results of OASIS II, a prospective randomized phase 2 trial in previously untreated mantle cell lymphoma patients.
Pr Steven Le Gouill

Abstract 5576 | Poster Bd 474
Genomic instability score (GIS) and benefit from olaparib (ola) and bevacizumab (bev) maintenance in high-grade ovarian cancer (HGOC): Phase III PAOLA-1 GINECO/ENGOT-ov25 trial exploratory analysis.
Dr Manuel Rodrigues

Abstract 2638 | Poster Bd 285
Randomized phase II trial evaluating the combination of TG4001, an HPV16 therapeutic vaccine, and avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic (R/M) HPV16-positive cervical or anogenital cancer.
Pr Christophe Le Tourneau

Abstract 1030 | Poster Bd 9
Efficacy of tucatinib, trastuzumab, and capecitabine (TTC) following trastuzumab-deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (MBC): Updated results and subgroup analyses from the UNICANCER multicenter retrospective cohort.
Dr Jean-Sebastien Frenel (Dr Delphine Loirat last autor)

Abstract 590 | Poster Bd 183
Post-treatment MRI to predict pathological complete response in triple-negative breast cancer following neoadjuvant chemoimmunotherapy.
Dr Toulsie Ramtohul

Abstract 552 | Poster Bd 145
Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC).
Dr Luc Cabel / Pr François-Clément Bidard

Investigating survival in patients undergoing surgery for pancreatic ductal adenocarcinoma using liquid biopsy: Preliminary results of PAN-CGE-BLISS pilot study. Alexandre Harlé, Julie Dardare, Margaux Betz, Cassandra Michel, Florence Schaffner, Jessica Demange, Marie Husson, Marie Rouyer, Pauline Gilson, Jean-Louis Merlin, Andréa Witz, CGE-Pancreas investigators